The US Food and Drug Administration and long-acting β2- agonists: The importance of striking the right balance between risks and benefits of therapy?

Journal of Allergy and Clinical Immunology

Volumn 126, Issue 3, 2010, Pages 449-452

  Lemanske Jr , Robert F ^a   Busse, William W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Asthma; asthma guidelines; long acting agonists

Indexed keywords

ALLERGEN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; SALMETEROL; SALBUTAMOL;

ASTHMA; CATARACT; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG LABELING; DRUG MEGADOSE; EDITORIAL; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; LOW DRUG DOSE; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SKIN; TREATMENT FAILURE; TREATMENT RESPONSE; VIRAL RESPIRATORY TRACT INFECTION; ANALOGS AND DERIVATIVES; DOSE CALCULATION; RISK FACTOR; STANDARDS; TIME; TREATMENT OUTCOME; UNITED STATES;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ALBUTEROL; ASTHMA; DRUG DOSAGE CALCULATIONS; DRUG LABELING; HUMANS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77956394681     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.05.039     Document Type: Editorial

References (19)

1. B.A. Chowdhury, and P.G. Dal The FDA and safe use of long-acting beta-agonists in the treatment of asthma N Engl J Med 362 2010 1169 1171
2. NAEPP3 Science base committee Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma - summary report 2007 J Allergy Clin Immunol 120 suppl 2007 S94 S138
3. H.S. Nelson, S.T. Weiss, E.R. Bleecker, S.W. Yancey, and P.M. Dorinsky The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol Chest 129 2006 15 26
4. S.C. Lazarus, H.A. Boushey, J.V. Fahy, V.M. Chinchilli, R.F. Lemanske Jr., and C.A. Sorkness Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial JAMA 285 2001 2583 2593
5. R.F. Lemanske Jr., C.A. Sorkness, E.A. Mauger, S.C. Lazarus, H.A. Boushey, and J.V. Fahy Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial JAMA 285 2001 2594 2603
6. R. Jaeschke, P.M. O'Byrne, F. Mejza, P. Nair, W. Lesniak, and J. Brozek The safety of long-acting β-agonists among patients with asthma using inhaled corticosteroids Am J Respir Crit Care Med 178 2008 1009 1016
7. M. Weatherall, M. Wijesinghe, K. Perrin, M. Harwood, and R. Beasley Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy Thorax 65 2010 39 43
8. Global Initiative for Asthma, National Heart, Lung, and Blood Institute. Global strategy for asthma management and prevention. Available at: http://www.ginasthma.com. Accessed 2009.
9. E.D. Bateman, L. Jacques, C. Goldfrad, T. Atienza, T. Mihaescu, and M. Duggan Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down J Allergy Clin Immunol 117 2006 563 570
10. P. Godard, P. Greillier, B. Pigearias, G. Nachbaur, J.L. Desfougeres, and V. Attali Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomised study Respir Med 102 2008 1124 1131
11. S.M. Koenig, N. Ostrom, D. Pearlman, K. Waitkus-Edwards, S. Yancey, and B.A. Prillaman Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down. " J Asthma 45 2008 681 687
12. E.D. Bateman, H.A. Boushey, J. Bousquet, W.W. Busse, T.J. Clark, and R.A. Pauwels Can guideline-defined asthma control be achieved?: The gaining optimal asthma control study Am J Respir Crit Care Med 170 2004 836 844
13. E. Bateman, H. Nelson, J. Bousquet, K. Kral, L. Sutton, and H. Ortega Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events Ann Intern Med 149 2008 33 42
14. H. Nelson, C. Bonuccelli, F. Radner, A. Ottosson, K.J. Carroll, and T.L. Andersson Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials J Allergy Clin Immunol 125 2010 390 396
15. R.J. Martin, S.J. Szefler, V.M. Chinchilli, M. Kraft, M. Dolovich, and H.A. Boushey Systemic effect comparisons of six inhaled corticosteroid preparations Am J Respir Crit Care Med 165 2002 1377 1383
16. S.J. Szefler, R.J. Martin, T.S. King, H.A. Boushey, R.M. Cherniack, and V.M. Chichilli Significant variability in response to inhaled corticosteroids for persistent asthma J Allergy Clin Immunol 109 2002 410 418
17. R.F. Lemanske Jr., D.T. Mauger, C.A. Sorkness, D.J. Jackson, S.J. Boehmer, and F.D. Martinez Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids N Engl J Med 362 2010 975 985
18. J.M. Kramer Balancing the benefits and risks of inhaled long-acting beta-agonists - the influence of values N Engl J Med 360 2009 1592 1595
19. R.L. DiSantostefano, K.J. Davis, S. Yancey, and C. Crim Ecologic analysis of asthma-related events and dispensing of inhaled corticosteroid- and salmeterol-containing products Ann Allergy Asthma Immunol 100 2008 558 565